drugset / Trial / NCT01423318
A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the safety and pharmacokinetics of subcutaneous lebrikizumab in healthy Japanese volunteers. Healthy Japanese and Caucasian volunteers will be randomized to receive a single subcutaneous dose of either lebrikizumab or placebo.
Timeline
- Start
- 2011-08
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lebrikizumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.